Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

A Second Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8

Clinical Trial Details — Status: Available

Administrative data

• NCT number: NCT05281484
• Other study ID #: CNMAu8.EAP02
• Status: Available

Study information

• Verified date: May 2024
• Source: Clene Nanomedicine
• Contact: Austin Rynders, BS
• Phone: (801)676-9695
• Email: info[@]clene.com
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

The primary objective of the intermediate expanded access protocol is to provide access to the investigational product, CNM-Au8, to up to 300 people living with ALS (pALS). No formal clinical hypotheses are being evaluated with concurrent controls. Secondary objectives include assessment of the safety of CNM-Au8 treatment in pALS. Safety will be assessed through the frequency of serious adverse events (SAEs), treatment-emergent adverse events (TEAEs) assessed as 'severe', discontinuations due to TEAEs, and laboratory abnormalities assessed as clinically significant during routine clinical monitoring (as applicable).

Description:

This is a multi-center intermediate expanded access program to provide access to the investigational product, CNM-Au8, up to 300 participants diagnosed with ALS. The safety of CNM-Au8 treatment in ALS participants will be evaluated. Visits will occur at a clinic or remotely via telephone or video-visit. Visits may be conducted remotely due to COVID-19-related pandemic concerns, or if due to ALS disease progression. Participants who meet the inclusion criteria and none of the exclusionary criteria may be enrolled into the EAP. There will be three study periods: 1. A treatment period of forty-eight (48) weeks (Treatment Period 1); 2. Additional optional follow-on treatment period(s) of up to forty-eight (48) weeks duration may be added at the discretion of the Sponsor and Site Investigator (e.g., Treatment Period 2, Treatment Period 3); 3. A four (4) week safety follow-up period (End-of-Study [EOS]Assessment). All participants will receive open-label oral treatment daily up to 48 weeks during Treatment Period 1. Additional 48-week treatment periods may be approved at the discretion of the Sponsor. The EAP may be discontinued at any time at the Sponsor's discretion. At treatment discontinuation or following the end of the participant's final Treatment Period, participants will complete an end-of-study (EOS) assessment 4 weeks following discontinuation of the investigational drug product. Visit assessments may be collected remotely, via tele-visit with study site staff. Investigational product may be shipped by the site to participants who do attend in-clinic visits.

Recruitment information / eligibility

• Status: Available
• Enrollment: 0
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able to understand and give written informed consent.

2. Male or female participants aged 18 years or greater (inclusive) at the time of ALS diagnosis.

3. Participants with a confirmed diagnosis of ALS per Gold Coast criteria as determined by a neurologist specializing in ALS (e.g., the site principal investigator or sub-investigator for this study).

4. Participant is able to daily consume up to 240 mL of the investigational drug suspension without substantial dysphagia, OR can intake the investigational product through a gastrostomy tube.

5. Participant must have completed standard clinical safety labs within the prior 90 days from the Baseline visit including a chemistry panel (e.g., CMP) and a hematology panel (e.g., CBC).

6. In the judgement of the Investigator the participant's expected survival is greater than six-months.

7. Participants who have established care with a neurologist at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the EAP within the United States. OR Prior participation in the HEALEY Platform ALS trial (Regimen C) Open Label Extension (NCT04414345) will be considered an automatic inclusion.

Exclusion Criteria:

1. Participant is eligible for participation in: (i) the HEALEY ALS Platform trial (NCT04297683), or (ii) any active study investigating CNM-Au8 for the treatment of ALS.

2. Participant has a history of any clinically significant or unstable medical condition (other than ALS) that may interfere with assessment of safety or compromise the study objectives.

3. Based on the investigator's judgment, participants who may have difficulty complying with the protocol and/or any study procedures.

4. Within the prior 90-days the participant has had clinically significant findings on standard hepatic, hematologic, or renal safety assays.

5. Participant is currently involved in another placebo-controlled clinical trial (note:

concomitant therapy with other investigational products is permitted with certain restrictions.

6. Females who are pregnant or nursing or who plan to get pregnant during the EAP or within 6 months of the end of this trial.

7. Females of child-bearing potential, or men, who are unwilling or unable to use accepted methods of birth control.

8. History of gold allergy. OR These exclusion criteria will not be applied if the participant was previously enrolled in the HEALEY Platform ALS trial (Regimen C) Open Label Extension (NCT04414345).

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Drug:
• CNM-Au8
CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids). Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm).

Locations

Country	Name	City	State
United States	Northwestern	Chicago	Illinois
United States	Texas Neurology	Dallas	Texas
United States	Nova Southeastern University	Davie	Florida
United States	Henry Ford Health Systems	Detroit	Michigan
United States	DUKE University Medical Center	Durham	North Carolina
United States	University of Kansas	Fairway	Kansas
United States	Penn State Health	Hershey	Pennsylvania
United States	Hospital for Special Care	New Britain	Connecticut
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	UC Irvine	Orange	California
United States	Jefferson Hospital	Philadelphia	Pennsylvania
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Barrow Neurological Institute	Phoenix	Arizona
United States	Providence Health	Portland	Oregon
United States	Sutter Health	San Francisco	California
United States	University of Washington	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Clene Nanomedicine

Country where clinical trial is conducted

United States,